

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	6345329
<b>Application Number:</b>	10590301
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7158
<b>Title of Invention:</b>	Synergistic Anti-Inflammatory Pharmaceutical Compositions and Methods of Use
<b>First Named Inventor/Applicant Name:</b>	John G. Babish
<b>Correspondence Address:</b>	Simona Levi-Minzi McDermott Will & Emery 28 State Street - Boston MA 02109 US - -
<b>Filer:</b>	Atabak R Royae/Jacqueline Andreu
<b>Filer Authorized By:</b>	Atabak R Royae
<b>Attorney Docket Number:</b>	068911-0169
<b>Receipt Date:</b>	28-OCT-2009
<b>Filing Date:</b>	01-MAY-2007
<b>Time Stamp:</b>	12:39:47
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$2060

RAM confirmation Number	8321				
Deposit Account	501133				
Authorized User					
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:					
Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)					
<b>File Listing:</b>					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Extension of Time	Extension.pdf	39795	no	1
			2ebc392960f2e87e8978daed9133dea89836998		
<b>Warnings:</b>					
<b>Information:</b>					
2	Request for Continued Examination (RCE)	RCE.pdf	797488	no	3
			308248cc5c5153c3b3bbf34eea652a962bde3e83		
<b>Warnings:</b>					
<b>Information:</b>					
3	Terminal Disclaimer Filed	Disclaimer.pdf	86589	no	1
			cb9a43855a90bcfab8d0e474eee79d2cd25e201f		
<b>Warnings:</b>					
<b>Information:</b>					
4		Amendment.pdf	390505	yes	10
			fc03e91799b339da0b11d7fcb0cf1a3bf906400		
	<b>Multipart Description/PDF files in .zip description</b>				
	<b>Document Description</b>		<b>Start</b>	<b>End</b>	
	Amendment After Final		1	1	
	Amendment Copy Claims/Response to Suggested Claims		2	4	
	Applicant Arguments/Remarks Made in an Amendment		5	10	
<b>Warnings:</b>					
<b>Information:</b>					
5	Fee Worksheet (PTO-875)	fee-info.pdf	34027	no	2
			54de2ee0aee9085bf565b84b603cbe30fc1816ce		
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			1348404		

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**